ArticlePloS one2013
Annexin A1 on the surface of early apoptotic cells suppresses CD8+ T cell immunity.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 76 citations in OpenAlex.
- C-type lectin receptors: bone remodeling and therapeutic potential.Bone research · 2026Review
- Interpretable modality-aware mapping of gene regulation in single-cell multiomics with scMAGCA.Nature communications · 2026Article
- KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma.Angiogenesis · 2025Article
- Potential Impact of Extracorporeal Photopheresis on Trained Immunity and Organ Transplant Acceptance.Transplantation direct · 2025Article
- Targeting the Dectin-1 Receptor in Neuroinflammation: Therapeutic Implications for Neuropsychiatric Disorders.ACS chemical neuroscience · 2025Review
- Single-cell transcriptional dissection illuminates an evolution of immunosuppressive microenvironment during pancreatic ductal adenocarcinoma metastasis.Signal transduction and targeted therapy · 2025Article
- Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway.Journal for immunotherapy of cancer · 2024Article
- An overview of the regulatory role of annexin A1 in the tumor microenvironment and its prospective clinical application (Review).International journal of oncology · 2024Review
- A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo.Oncogene · 2024Article
- Highly pathogenic natural monoclonal antibody B4-IgM recognizes a post-translational modification comprised of acetylated N-terminal methionine followed by aspartic or glutamic acid.Molecular immunology · 2023Article
- Selective vulnerability of human-induced pluripotent stem cells to dihydroorotate dehydrogenase inhibition during mesenchymal stem/stromal cell purification.Frontiers in cell and developmental biology · 2023Article
- Molecular analysis of Annexin expression in cancer.BMC cancer · 2022Article
- Types of necroinflammation, the effect of cell death modalities on sterile inflammation.Cell death & disease · 2022Review
- Saliva based diagnostic methodologies for a fast track detection of autism spectrum disorder: A mini-review.Frontiers in neuroscience · 2022Review
- Dectin-1 Signaling Update: New Perspectives for Trained Immunity.Frontiers in immunology · 2022Review
- Emerging roles of Dectin-1 in noninfectious settings and in the CNS.Trends in immunology · 2021Review
- Review
- The holobiont transcriptome of teneral tsetse fly species of varying vector competence.BMC genomics · 2021Article
- Overcoming the blood-brain barrier by Annexin A1-binding peptide to target brain tumours.British journal of cancer · 2020Article
- Annexin V expression on CD4Immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prevention of an immune response against self-antigens derived from apoptotic cells is essential to preclude autoimmune and chronic inflammatory diseases. Here, we describe apoptosis induced externalization of endogenous cytosolic annexin 1 initiating an anti-inflammatory effector mechanism that suppresses the immune response against antigens of apoptotic cells. Cytosolic annexin 1 rapidly translocated to the apoptotic cell surface and inhibited dendritic cell (DC) activation induced by Toll like receptors (TLR). Annexin 1-inhibited DC showed strongly reduced secretion of pro-inflammatory cytokines (e.g. TNF and IL-12) and costimulatory surface molecules (e.g. CD40 and CD86), while anti-inflammatory mediators like PD-L1 remained unchanged. T cells stimulated by such DC lacked secretion of interferon-γ (IFN-γ) and TNF but retained IL-10 secretion. In mice, annexin 1 prevented the development of inflammatory DC and suppressed the cellular immune response against the model antigen ovalbumin (OVA) expressed in apoptotic cells. Furthermore, annexin 1 on apoptotic cells compromised OVA-specific tumor vaccination and impaired rejection of an OVA-expressing tumor. Thus, our results provide a molecular mechanism for the suppressive activity of apoptotic cells on the immune response towards apoptotic cell-derived self-antigens. This process may play an important role in prevention of autoimmune diseases and of the immune response against cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.